NCT02787369 2026-01-07
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
18 trialsNCT07166549 2025-12-24
BaseCAR-01
University Hospital, Basel, Switzerland
Phase 1 Not yet recruiting
NCT06208735 2025-12-15
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency
Phase 1 Recruiting
NCT02650414 2025-12-12
CD22 Redirected Autologous T Cells for ALL
University of Pennsylvania
Phase 1 Active not recruiting
NCT02050347 2025-11-14
CARPASCIO
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05010564 2025-11-13
TRICAR-ALL
Baylor College of Medicine
Phase 1 Recruiting
NCT03774654 2025-07-01
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Baylor College of Medicine
Phase 1 Active not recruiting
NCT01683279 2025-06-17
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT04260945 2022-03-08
CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients
Hebei Yanda Ludaopei Hospital
Phase 1 Completed
NCT03605589 2021-04-01
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
Phase 1 Withdrawn
NCT03599375 2019-02-26
Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
The First Hospital of Jilin University
Phase 1 Unknown
NCT03576807 2018-07-03
The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
Shanghai Longyao Biotechnology Inc., Ltd.
Phase 1 Unknown
NCT03463928 2018-03-13
A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
Chinese PLA General Hospital
Phase 1 Unknown
NCT01805375 2018-02-05
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
Cancer Research UK
Phase 1 Completed
NCT01400685 2018-01-25
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
Massachusetts General Hospital
Phase 1 Completed
NCT01362452 2017-08-03
Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02968472 2016-11-18
A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
The First People's Hospital of Yunnan
Phase 1 Unknown
NCT00990587 2015-06-22
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
University Health Network, Toronto
Phase 1 Completed